Crizotinib (CRZ), a first‐generation ALK inhibitor, studied in ALK+ pediatric ALCL and in adults with NSCLC showed good responses and prolonged survival.24, 25, 26, 27. This evidence concerns the gene ALK and non-small cell lung carcinoma.